Why the study?
Heart failure is frequently associated with anemia, which increases mortality and worsens quality of life, and treatments like ACE inhibitors and aldosterone receptor blockers may contribute to anemia development.
Do angiotensin-converting enzyme inhibitors and aldosterone receptor blockers contribute to the development of anemia in patients with heart failure?
Do angiotensin-converting enzyme inhibitors and aldosterone receptor blockers contribute to the development of anemia in patients with heart failure?
This review highlights the pathophysiological mechanisms of anemia in heart failure and its potential link to treatment with ACE inhibitors and aldosterone receptor blockers.
Suggests routine HF therapies may contribute to anemia; leaves open whether this mechanistic link warrants altering guideline.
Heart failure (HF) remains one of the most common diseases and one of the major causes of death worldwide. HF is often associated with other chronic diseases, most commonly with anemia. Anemia increases patients' mortality and lowers their quality of life. There are a few pathophysiological mechanisms that explain anemia in patients with HF - hemodilution, absolute or functional iron deficiency, activation of the inflammatory cascade, chronic kidney disease, and impaired erythropoietin production and activity. Moreover, congestive HF is often treated with angiotensin-converting enzyme inhibitors and aldosterone receptors blockers, which could be linked to the development of anemia.
No takes yet. Share an insight, caveat, or question.
A 2021 study studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: